Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning

Condition:   Prostate Cancer Intervention:   Drug: Pembrolizumab Sponsors:   CHU de Quebec-Universite Laval;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials